OPT - Afternoon delight on this biotech.2.11pm and 2.13pm trades superb.2 - 3 billion in annual expected revenues if their eye treatment gets up .Source AFR Pengana Capital.
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
